Multiple Reaction Monitoring-based, Multiplexed, Absolute Quantitation of 45 Proteins in Human Plasma*

Mass spectrometry-based multiple reaction monitoring (MRM) quantitation of proteins can dramatically impact the discovery and quantitation of biomarkers via rapid, targeted, multiplexed protein expression profiling of clinical samples. A mixture of 45 peptide standards, easily adaptable to common plasma proteomics work flows, was created to permit absolute quantitation of 45 endogenous proteins in human plasma trypsin digests. All experiments were performed on simple tryptic digests of human EDTA-plasma without prior affinity depletion or enrichment. Stable isotope-labeled standard peptides were added immediately following tryptic digestion because addition of stable isotope-labeled standard peptides prior to trypsin digestion was found to generate elevated and unpredictable results. Proteotypic tryptic peptides containing isotopically coded amino acids ([13C6]Arg or [13C6]Lys) were synthesized for all 45 proteins. Peptide purity was assessed by capillary zone electrophoresis, and the peptide quantity was determined by amino acid analysis. For maximum sensitivity and specificity, instrumental parameters were empirically determined to generate the most abundant precursor ions and y ion fragments. Concentrations of individual peptide standards in the mixture were optimized to approximate endogenous concentrations of analytes and to ensure the maximum linear dynamic range of the MRM assays. Excellent linear responses (r > 0.99) were obtained for 43 of the 45 proteins with attomole level limits of quantitation (<20% coefficient of variation) for 27 of the 45 proteins. Analytical precision for 44 of the 45 assays varied by <10%. LC-MRM/MS analyses performed on 3 different days on different batches of plasma trypsin digests resulted in coefficients of variation of <20% for 42 of the 45 assays. Concentrations for 39 of the 45 proteins are within a factor of 2 of reported literature values. This mixture of internal standards has many uses and can be applied to the characterization of trypsin digestion kinetics and plasma protein expression profiling because 31 of the 45 proteins are putative biomarkers of cardiovascular disease.

[1]  Robertson Craig,et al.  Open source system for analyzing, validating, and storing protein identification data. , 2004, Journal of proteome research.

[2]  W. Demark-Wahnefried,et al.  Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  R. Cooks,et al.  Multiple reaction monitoring in mass spectrometry/mass spectrometry for direct analysis of complex mixtures , 1978 .

[4]  Kym Faull,et al.  Characterization of serum biomarkers for detection of early stage ovarian cancer , 2005, Proteomics.

[5]  J. Griffiths,et al.  Multiple Reaction Monitoring to Identify Sites of Protein Phosphorylation with High Sensitivity *S , 2005, Molecular & Cellular Proteomics.

[6]  Werner Zolg,et al.  Quantification of C‐reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C‐labeled peptide standards , 2004, Proteomics.

[7]  Tetsuya Terasaki,et al.  Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria , 2008, Pharmaceutical Research.

[8]  R. Plumb,et al.  High-throughput quantification for a drug mixture in rat plasma-a comparison of Ultra Performance liquid chromatography/tandem mass spectrometry with high-performance liquid chromatography/tandem mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[9]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[10]  E. Duchoslav,et al.  Multiple reaction monitoring as a method for identifying protein posttranslational modifications. , 2005, Journal of biomolecular techniques : JBT.

[11]  Robertson Craig,et al.  The use of proteotypic peptide libraries for protein identification. , 2005, Rapid communications in mass spectrometry : RCM.

[12]  Chun-Ta Liao,et al.  Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. , 2005, Clinical chemistry.

[13]  M. Mann,et al.  Mass spectrometry–based proteomics turns quantitative , 2005, Nature chemical biology.

[14]  Leigh Anderson,et al.  Candidate‐based proteomics in the search for biomarkers of cardiovascular disease , 2005, The Journal of physiology.

[15]  Kelvin H. Lee,et al.  Quantitative analysis of protein expression using amine‐specific isobaric tags in Escherichia coli cells expressing rhsA elements , 2005, Proteomics.

[16]  Irina Kusmartseva,et al.  Panel of serum biomarkers for the diagnosis of lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[18]  A. Stieg,et al.  Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. , 2003, Urology.

[19]  Henry H. N. Lam,et al.  PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows , 2008, EMBO reports.

[20]  J. Green,et al.  Peer Reviewed: A Practical Guide to Analytical Method Validation , 1996 .

[21]  Mu Wang,et al.  A multiple reaction monitoring method for absolute quantification of the human liver alcohol dehydrogenase ADH1C1 isoenzyme. , 2007, Analytical biochemistry.

[22]  S. Ha,et al.  Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease , 2007, BMC neurology.

[23]  K Kronkvist,et al.  Automated sample preparation for the determination of budesonide in plasma samples by liquid chromatography and tandem mass spectrometry. , 1998, Journal of chromatography. A.

[24]  Matthias Mann,et al.  Mass spectrometric-based approaches in quantitative proteomics. , 2003, Methods.

[25]  S. Carr,et al.  Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S , 2007, Molecular & Cellular Proteomics.

[26]  N Leigh Anderson,et al.  High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. , 2008, Clinical chemistry.

[27]  Jinxiang Han,et al.  Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients , 2008, BMC Cancer.

[28]  Bindu Nanduri,et al.  Prediction of peptides observable by mass spectrometry applied at the experimental set level , 2007, BMC Bioinformatics.

[29]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[30]  M. Berna,et al.  Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers , 2007, Expert review of proteomics.

[31]  S. Edge,et al.  Downregulation of Gelsolin Correlates with the Progression to Breast Carcinoma , 2004, Breast Cancer Research and Treatment.

[32]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[33]  Hoguen Kim,et al.  Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations , 2006, Proteomics.

[34]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[35]  T. Shaler,et al.  Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap. , 2006, Analytical chemistry.

[36]  John R Yates,et al.  Influence of basic residue content on fragment ion peak intensities in low-energy collision-induced dissociation spectra of peptides. , 2004, Analytical chemistry.

[37]  Steven P Gygi,et al.  The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. , 2005, Methods.

[38]  Nam-Soon Kim,et al.  Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. , 2006, International journal of oncology.

[39]  Fagen Zhang,et al.  Quantitation of human glutathione S-transferases in complex matrices by liquid chromatography/tandem mass spectrometry with signature peptides. , 2004, Rapid communications in mass spectrometry : RCM.

[40]  S. Wisniewski,et al.  Plasma and cerebrospinal fluid α1‐antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment , 2003, Annals of neurology.

[41]  William E Grizzle,et al.  Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  S. Goodison,et al.  Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. , 2007, Journal of proteome research.

[43]  J. Mehta,et al.  Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. , 1996, American heart journal.

[44]  Tasneem H. Patwa,et al.  Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. , 2008, Journal of proteome research.

[45]  D. Chace Mass spectrometry in the clinical laboratory. , 2001, Chemical reviews.

[46]  E. Hawe,et al.  Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[47]  W. Demark-Wahnefried,et al.  Zinc α-2-Glycoprotein Is Expressed by Malignant Prostatic Epithelium and May Serve as a Potential Serum Marker for Prostate Cancer , 2001 .

[48]  P. Oeller,et al.  Global proteome discovery using an online three-dimensional LC-MS/MS. , 2005, Journal of proteome research.

[49]  S. Kingsmore Multiplexed protein measurement: technologies and applications of protein and antibody arrays , 2006, Nature Reviews Drug Discovery.

[50]  E Vuori,et al.  Simultaneous screening for 238 drugs in blood by liquid chromatography-ion spray tandem mass spectrometry with multiple-reaction monitoring. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[51]  G. Hall,et al.  Proteomic Profiling Identifies Afamin as a Potential Biomarker for Ovarian Cancer , 2007, Clinical Cancer Research.

[52]  Daniel B. Martin,et al.  Computational prediction of proteotypic peptides for quantitative proteomics , 2007, Nature Biotechnology.

[53]  George G Klee,et al.  Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. , 2004, Journal of proteome research.